The stock of BioNTech SE ADR (NASDAQ:BNTX) last traded at $92.25, down -0.77% from the previous session.
BNTX stock price is now -1.48% away from the 50-day moving average and -10.44% away from the 200-day moving average. The market capitalization of the company currently stands at $21.93B.
With the price target of $127, BMO Capital Markets recently initiated with Outperform rating for BioNTech SE ADR (NASDAQ: BNTX). , while ‘JP Morgan’ rates the stock as ‘Underweight’
A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, BioNTech SE ADR has had a low of $85.21 and a high of $131.52. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 9.43, and a quick ratio of 9.26. The fifty day moving average price for BNTX is $93.64 and a two-hundred day moving average price translates $103.01 for the stock.
The latest earnings results from BioNTech SE ADR (NASDAQ: BNTX) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $2.06, missing analysts’ expectations of $2.62 by -0.56. This compares to $9.92 EPS in the same period last year. The net profit margin was 24.26% and return on equity was 4.56% for BNTX. The company reported revenue of $1.61 billion for the quarter, compared to $4.2 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -61.75 percent. For the current quarter, analysts expect BNTX to generate $464.65M in revenue.
BioNTech SE ADR(BNTX) Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
